Sun Pharma, Lupin Recall Over 41,500 Drug Bottles In U.S.
Domestic drug majors Sun Pharmaceutical Industries and Lupin are recalling 41,737 bottles of three drugs used for various ailments such as high blood pressure, depression, and anxiety in the U.S.
Sun Pharmaceutical Industries Inc is recalling 12,109 bottles of Carvediol tablets USP used for treatment of high blood pressure, according to the latest Enforcement Report of the US Food and Drug Administration (U.S. FDA).
The recall covers tablets in strengths of 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg in the US in a ongoing voluntary nationwide recall, it added.
The recall is due to "failed impurities/degradation specifications," the report said.
The tablets were manufactured at Hungary based ALKALOIDA Chemical Company Zrt, which is a subsidiary of Sun Pharma.
On the other hand, Lupin is recalling 3,192 bottles of Escitalopram and 26,436 bottles of Lisinopril tablets.
While Escitalopram tablets are used for treatment of depression and anxiety, Lisinopril tablets are indicated for treating hypertension.
The recall of Escitalopram tablets USP in the strength of 20 mg is on account of "Labeling: incorrect or missing lot and/or expiration date," the report said.
The product was made for Lupin Pharmaceuticals Baltimore by Lupin at its Goa facility.
As per the report, Lupin's recall of Lisinopril tablets for strengths of 30 mg and 40 mg is on account of GMP deviations as the finished products were manufactured using active pharmaceutical ingredients, whose intermediates failed specifications.
The product was made at Lupin's Pithampur facility, it added.
All the three voluntary ongoing recalls are class III, the enforcement report said.
As per the USFDA, class III recall is initiated in a situation "in which use of, or exposure to, a violative product is not likely to cause adverse health consequences."
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.